Equities researchers at Brookline Capital Management decreased their FY2025 earnings per share estimates for shares of OS Therapies in a research note issued to investors on Wednesday, April 2nd.

Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share estimates for OS Therapies in a research report issued to clients and investors on Wednesday, April 2nd.

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

Explore OS Therapies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OSTX. Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer ...

“2024 was a transformative year for OS Therapies as we completed our initial public offering and finalized the treatment phase of our Phase 2b clinical trial in the prevention of recurrence in ...

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy OS Therapies (NYSE-A: OSTX) (“OS Therapies” or ...